Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5091MR)

This product GTTS-WQ5091MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5091MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12799MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ11152MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ6761MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ9007MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ12474MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ10631MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ4777MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2772MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW